Commonwealth Financial Services LLC Purchases Shares of 361 Axon Enterprise, Inc $AXON

Commonwealth Financial Services LLC purchased a new stake in Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 361 shares of the biotechnology company’s stock, valued at approximately $299,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Hemington Wealth Management increased its stake in Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 17 shares during the last quarter. TCTC Holdings LLC increased its stake in Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 24 shares during the last quarter. Bartlett & CO. Wealth Management LLC grew its position in shares of Axon Enterprise by 132.0% in the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 33 shares during the period. Catalyst Capital Advisors LLC bought a new position in shares of Axon Enterprise in the 1st quarter valued at about $32,000. Finally, Banque Transatlantique SA bought a new position in shares of Axon Enterprise in the 1st quarter valued at about $31,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Axon Enterprise

In related news, CFO Brittany Bagley sold 5,000 shares of Axon Enterprise stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the completion of the sale, the chief financial officer owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. The trade was a 5.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $752.54, for a total transaction of $75,254.00. Following the sale, the director directly owned 1,416 shares of the company’s stock, valued at $1,065,596.64. The trade was a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,932 shares of company stock worth $45,115,616 in the last ninety days. Insiders own 4.40% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON stock opened at $703.03 on Friday. The company has a market capitalization of $55.19 billion, a price-to-earnings ratio of 173.59, a PEG ratio of 27.30 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The company has a 50-day simple moving average of $755.57 and a 200 day simple moving average of $713.70. Axon Enterprise, Inc has a 52 week low of $422.38 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, topping the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise’s revenue was up 32.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AXON shares. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a research report on Tuesday, August 5th. Piper Sandler started coverage on shares of Axon Enterprise in a research report on Tuesday, September 23rd. They issued an “overweight” rating and a $893.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and issued a $870.00 price objective on shares of Axon Enterprise in a research report on Wednesday, September 24th. Raymond James Financial reissued an “outperform” rating and issued a $855.00 price objective (up previously from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Finally, JMP Securities reissued a “market outperform” rating and issued a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and a consensus target price of $841.64.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.